August 11, 2020

 

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attn:

Mr. Alan Campbell

and Ms. Suzanne Hayes

 

Re:

CureVac B.V.

Registration Statement on Form F-1

File No. 333-240076

 

Acceleration Request

Requested Date: August 13, 2020

Requested Time: 4:00 p.m., Eastern Standard Time

 

Ladies and Gentlemen:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), BofA Securities, Inc., Jefferies LLC and Credit Suisse Securities (USA) LLC, as representatives of the several underwriters, hereby joins CureVac B.V. in requesting that the Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form F-1 (File No. 333-240076) (the “Registration Statement”) to become effective on August 13, 2020, at 4:00 p.m., Eastern Standard Time, or as soon as practicable thereafter.

 

Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

 

We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

 

[Signature Page Follows]

 

 

 

	Very truly yours,
	BofA Securities, Inc.
	By:	/s/ Michele Allong
	Name:	Michele Allong
	Title:	Authorized Signatory

 

	JEFFERIES LLC
	By:	/s/ Matthew Kim
	Name:	Matthew Kim
	Title:	Managing Director

 

 

	Credit Suisse Securities (USA) LLC
	By:	/s/ Joshua Pinto
	Name:	Joshua Pinto
	Title:	Director

 

 

cc:

Franz-Werner Haas, CureVac B.V.

Richard D. Truesdell Jr., Davis Polk & Wardwell LLP

Nathan Ajiashvili, Latham & Watkins LLP